精神分裂症患者骨代谢影响因素的研究进展

doi:10.3969/j.issn.1674-8115.2021.07.021

摘要/Abstract

摘要：

精神分裂症患者与普通人群相比发生低骨密度、骨质疏松和骨折的风险更高，这不仅影响了患者的生活质量，而且影响其长期结局。既往研究表明，影响个体骨代谢的因素有很多，包括药物、性别、年龄、性腺功能和生活方式等。该文结合临床研究，从疾病本身、使用抗精神病药物及不良的生活方式3个方面进行综述，探讨了精神分裂症患者骨代谢可能的影响因素，并简单阐述了骨质疏松的诊断和干预措施，为临床预防和干预精神分裂症患者的骨质疏松提供依据。

关键词: 精神分裂症, 骨质疏松, 骨代谢, 抗精神病药物

Abstract:

The patients with schizophrenia experience a higher rate of low bone mineral density, osteoporosis and fractures than the general population, which affects not only their quality of life but also their long-term outcomes. Previous studies have shown that there are many factors affecting individual bone metabolism, including drugs, gender, age, hypogonadism, lifestyle, etc. Combined with clinical research, this article summarizes three aspects, i.e.,the disease itself, the use of antipsychotics and the unhealthy lifestyle. This review aims to discuss the influencing factors of bone metabolism in the patients with schizophrenia, and then expound briefly on the diagnosis and intervention measures of osteoporosis, which may provide a reference for clinical prevention and intervention of osteoporosis in the patients with schizophrenia.

Key words: schizophrenia, osteoporosis, bone metabolism, antipsychotics

中图分类号:

R749.3

轩红艳, 王丽华, 李华芳. 精神分裂症患者骨代谢影响因素的研究进展[J]. 上海交通大学学报(医学版), 2021, 41(7): 972-976.

Hong-yan XUAN, Li-hua WANG, Hua-fang LI. Review of the factors influencing bone metabolism in schizophrenia[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(7): 972-976.

参考文献 50

1	Stubbs B, De Hert M, Sepehry AA, et al. A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia[J]. Acta Psychiatr Scand, 2014, 130(6): 470-486.
2	Cui JY, Liu HQ, Shao J, et al. Prevalence, risk factors and clinical characteristics of osteoporosis in Chinese inpatients with schizophrenia[J]. Schizophr Res, 2018, 195: 488-494.
3	Tseng PT, Chen YW, Yeh PY, et al. Bone mineral density in schizophrenia: an update of current meta-analysis and literature review under guideline of PRISMA[J]. Medicine (Baltimore), 2015, 94(47): e1967.
4	Partti K, Heliövaara M, Impivaara O, et al. Skeletal status in psychotic disorders: a population-based study[J]. Psychosom Med, 2010, 72(9): 933-940.
5	冒雷明, 周春英, 胡亚兰, 等. 首发精神分裂症患者骨密度检测及影响因素分析[J]. 临床心身疾病杂志, 2017, 23(6): 168-170.
6	Mayne PE, Burne THJ. Vitamin D in synaptic plasticity, cognitive function, and neuropsychiatric illness[J]. Trends Neurosci, 2019, 42(4): 293-306.
7	Berg AO, Jørgensen KN, Nerhus M, et al. Vitamin D levels, brain volume, and genetic architecture in patients with psychosis[J]. PLoS One, 2018, 13(8): e0200250.
8	Allott K, McGorry PD, Yuen HP, et al. The vitamins in psychosis study: a randomized, double-blind, placebo-controlled trial of the effects of vitamins B₁₂, B₆, and folic acid on symptoms and neurocognition in first-episode psychosis[J]. Biol Psychiatry, 2019, 86(1): 35-44.
9	Hubbard DB, Miller BJ. Meta-analysis of blood cortisol levels in individuals with first-episode psychosis[J]. Psychoneuroendocrinology, 2019, 104: 269-275.
10	Gyllenberg D, Sourander A, Surcel HM, et al. Hypothyroxinemia during gestation and offspring schizophrenia in a national birth cohort[J]. Biol Psychiatry, 2016, 79(12): 962-970.
11	Kočovská E, Gaughran F, Krivoy A, et al. Vitamin-D deficiency as a potential environmental risk factor in multiple sclerosis, schizophrenia, and autism[J]. Front Psychiatry, 2017, 8: 47.
12	van der Leeuw C, de Witte LD, Stellinga A, et al. Vitamin D concentration and psychotic disorder: associations with disease status, clinical variables and urbanicity[J]. Psychol Med, 2020, 50(10): 1680-1686.
13	Valipour G, Saneei P, Esmaillzadeh A. Serum vitamin D levels in relation to schizophrenia: a systematic review and meta-analysis of observational studies[J]. J Clin Endocrinol Metab, 2014, 99(10): 3863-3872.
14	Taylor AE, Burgess S, Ware JJ, et al. Investigating causality in the association between 25(OH)D and schizophrenia[J]. Sci Rep, 2016, 6: 26496.
15	Crews M, Lally J, Gardner-Sood P, et al. Vitamin D deficiency in first episode psychosis: a case-control study[J]. Schizophr Res, 2013, 150(2/3): 533-537.
16	Lally J, Ajnakina O, Singh N, et al. Vitamin D and clinical symptoms in First Episode Psychosis (FEP): a prospective cohort study[J]. Schizophr Res, 2019, 204: 381-388.
17	Muscogiuri G, Altieri B, de Angelis C, et al. Shedding new light on female fertility: the role of vitamin D[J]. Rev Endocr Metab Disord, 2017, 18(3): 273-283.
18	Levine J, Stahl Z, Sela BA, et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia[J]. Biol Psychiatry, 2006, 60(3): 265-269.
19	Petronijević ND, Radonjić NV, Ivković MD, et al. Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2008, 32(8): 1921-1926.
20	Weber DR, Coughlin C, Brodsky JL, et al. Low bone mineral density is a common finding in patients with homocystinuria[J]. Mol Genet Metab, 2016, 117(3): 351-354.
21	Cherian K, Schatzberg AF, Keller J. HPA axis in psychotic major depression and schizophrenia spectrum disorders: cortisol, clinical symptomatology, and cognition[J]. Schizophr Res, 2019, 213: 72-79.
22	Girshkin L, Matheson SL, Shepherd AM, et al. Morning cortisol levels in schizophrenia and bipolar disorder: a meta-analysis[J]. Psychoneuroen-docrinology, 2014, 49: 187-206.
23	Hardy RS, Zhou H, Seibel MJ, et al. Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy[J]. Endocr Rev, 2018, 39(5): 519-548.
24	Noda M. Possible role of glial cells in the relationship between thyroid dysfunction and mental disorders[J]. Front Cell Neurosci, 2015, 9: 194.
25	Sharif K, Tiosano S, Watad A, et al. The link between schizophrenia and hypothyroidism: a population-based study[J]. Immunol Res, 2018, 66(6): 663-667.
26	Williams GR, Bassett JHD. Thyroid diseases and bone health[J]. J Endocrinol Invest, 2018, 41(1): 99-109.
27	Nikolić T, Petronijević M, Sopta J, et al. Haloperidol affects bones while clozapine alters metabolic parameters-sex specific effects in rats perinatally treated with phencyclidine[J]. BMC Pharmacol Toxicol, 2017, 18(1): 65.
28	Zhang BB, Deng L, Wu HS, et al. Relationship between long-term use of a typical antipsychotic medication by Chinese schizophrenia patients and the bone turnover markers serum osteocalcin and β-CrossLaps[J]. Schizophr Res, 2016, 176(2/3): 259-263.
29	Bolton JM, Morin SN, Majumdar SR, et al. Association of mental disorders and related medication use with risk for major osteoporotic fractures[J]. JAMA Psychiatry, 2017, 74(6): 641-648.
30	Inder WJ, Castle D. Antipsychotic-induced hyperprolactinaemia[J]. Aust N Z J Psychiatry, 2011, 45(10): 830-837.
31	Bernard V, Young J, Binart N. Prolactin-a pleiotropic factor in health and disease[J]. Nat Rev Endocrinol, 2019, 15(6): 356-365.
32	Liang MN, Zhang BB, Deng L, et al. Effects of olanzapine on bone mineral density, glucose, and lipid metabolism in schizophrenia patients[J]. Int J Endocrinol, 2019, 2019: 1312804.
33	Gomez L, Stubbs B, Shirazi A, et al. Lower bone mineral density at the hip and lumbar spine in people with psychosis versus controls: a comprehensive review and skeletal site-specific meta-analysis[J]. Curr Osteoporos Rep, 2016, 14(6): 249-259.
34	李艳歌, 于文娟, 沈一峰, 等. 抗精神病药治疗精神分裂症导致催乳素水平差异的机制[J]. 上海交通大学学报(医学版), 2018, 38(7): 797-800.
35	Wang MX, Hou RH, Jian J, et al. Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study[J]. Hum Psychopharmacol, 2014, 29(2): 183-189.
36	Meaney AM, O'Keane V. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables[J]. Schizophr Res, 2007, 93(1-3): 136-143.
37	Lodhi RJ, Masand S, Malik A, et al. Changes in biomarkers of bone turnover in an aripiprazole add-on or switching study[J]. Schizophr Res, 2016, 170(2/3): 245-251.
38	Abraham G, Paing WW, Kaminski J, et al. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study[J]. Am J Psychiatry, 2003, 160(9): 1618-1620.
39	van der Leeuw C, Peeters S, Domen P, et al. Bone mineral density as a marker of cumulative estrogen exposure in psychotic disorder: a 3 year follow-up study[J]. PLoS One, 2015, 10(8): e0136320.
40	Clapham E, Bodén R, Reutfors J, et al. Exposure to risperidone versus other antipsychotics and risk of osteoporosis-related fractures: a population-based study[J]. Acta Psychiatr Scand, 2020, 141(1): 74-83.
41	Park YM, Lee SH, Lee BH, et al. Prolactin and macroprolactin levels in psychiatric patients receiving atypical antipsychotics: a preliminary study[J]. Psychiatry Res, 2016, 239: 184-189.
42	Kim HY, Choe JW, Kim HK, et al. Negative association between metabolic syndrome and bone mineral density in Koreans, especially in men[J]. Calcif Tissue Int, 2010, 86(5): 350-358.
43	Lin CH, Lin CY, Wang HS, et al. Long-term use of clozapine is protective for bone density in patients with schizophrenia[J]. Sci Rep, 2019, 9(1): 3895.
44	Qiu J, Gong HX, Wang BX, et al. The use of clozapine is protective for low bone mineral density induced by prolactin-raising antipsychotics in inpatients with schizophrenia[J]. Arch Osteoporos, 2020, 15(1): 98.
45	Faulkner G, Cohn T, Remington G. Validation of a physical activity assessment tool for individuals with schizophrenia[J]. Schizophr Res, 2006, 82(2/3): 225-231.
46	Mallet J, Le Strat Y, Schürhoff F, et al. Cigarette smoking and schizophrenia: a specific clinical and therapeutic profile? Results from the FACE-Schizophrenia cohort[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2017, 79(Pt B): 332-339.
47	Volkow ND. Substance use disorders in schizophrenia: clinical implications of comorbidity[J]. Schizophr Bull, 2009, 35(3): 469-472.
48	Roick C, Fritz-Wieacker A, Matschinger H, et al. Health habits of patients with schizophrenia[J]. Soc Psychiatry Psychiatr Epidemiol, 2007, 42(4): 268-276.
49	张智海, 刘忠厚, 李娜, 等. 中国人骨质疏松症诊断标准专家共识(第三稿·2014版)[J]. 中国骨质疏松杂志, 2014, 20(9): 1007-1010.
50	中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 原发性骨质疏松症基层诊疗指南(2019年)[J]. 中华全科医师杂志, 2020, 19(4): 304-315.

[1]	宋兵福, 丁彬彬, 张晓丽, 姚莉韵. 二甲双胍对喹硫平致精神分裂症患者糖脂代谢紊乱的疗效[J]. 上海交通大学学报(医学版), 2021, 41(6): 776-780.
[2]	胡国芹, 杨程青, 吕钦谕, 赵静, 朱明环, 易正辉, 戴兴海. 计算机化认知矫正治疗对精神分裂症患者认知功能的影响[J]. 上海交通大学学报(医学版), 2021, 41(5): 622-627.
[3]	蔡苗苗, 高艳虹. 肌少-骨质疏松症的研究进展[J]. 上海交通大学学报(医学版), 2021, 41(5): 678-683.
[4]	阳红, 黄欣欣, 刘超, 梁青松, 杨华, 张建标, 徐健, 王颖怡, 吴海苏, 吕钦谕, 易正辉. 突触结合蛋白2基因多态性与中国汉族精神分裂症的关联研究[J]. 上海交通大学学报(医学版), 2021, 41(1): 16-22.
[5]	胡国芹, 吕钦谕, 赵静, 朱明环, 禹顺英, 易正辉, 陈健. NOS1AP基因非编码区位点多态性与精神分裂症的关联研究[J]. 上海交通大学学报(医学版), 2021, 41(1): 29-34.
[6]	栾风焕1，叶惠玲2，徐璐1，范青2，宋立升2. 社交技能训练在门诊精神分裂症患者中的应用研究[J]. 上海交通大学学报（医学版）, 2020, 40(4): 500-.
[7]	王峰伟1，沈秋明1，拉巴仓拉1，施悦1，张舒娴1，王沪雯1，常睿捷1，杨颖华2，万和平3，沈恬1，蔡泳1. 上海市社区中老年居民骨质疏松症预防相关路径分析[J]. 上海交通大学学报（医学版）, 2020, 40(4): 525-.
[8]	李娜1，安宇2，张永录3，丁志杰3，吴柏林4，兰小平5, 6. 中国汉族人群GAD1和GABRB3基因启动子区单核苷酸多态性与精神分裂症的关联研究[J]. 上海交通大学学报（医学版）, 2020, 40(3): 310-.
[9]	李旋1，项琼1，占燕2，朱殿明1，卓恺明1，王亚3，陈海莹1，刘登堂1. 首发精神分裂症患者基于事件前瞻记忆缺陷的心理机制研究[J]. 上海交通大学学报（医学版）, 2020, 40(2): 208-.
[10]	文万军1，陈晔1，覃宗厚1，吕望强2，唐伟3，卢卫红4，范卫星2，张晨4. 血清白介素-6水平与精神分裂症伴抑郁症状之间的关系[J]. 上海交通大学学报(医学版), 2020, 40(12): 1618-1620.
[11]	任延燕，吕钦谕，杨伟丽，王振. 早年创伤与精神分裂症症状的相关性[J]. 上海交通大学学报(医学版), 2020, 40(12): 1641-1645.
[12]	项思莹，李宁宁，徐一峰#，陈剑华#. 抗精神病药物诱发代谢综合征的DNA甲基化研究进展[J]. 上海交通大学学报(医学版), 2020, 40(12): 1656-1659.
[13]	崔雅琦，白玉冰，许怡晨，谭心辰，李梦莹，贾浩. 脂肪来源的间充质干细胞及外囊泡促成骨分化的研究进展[J]. 上海交通大学学报(医学版), 2020, 40(12): 1672-1676.
[14]	黄燕1，张宪高2，林亨1，程淑英1. 重复经颅磁刺激对精神分裂症疗效及安全性研究的meta分析[J]. 上海交通大学学报（医学版）, 2020, 40(1): 81-.
[15]	张建标1，吕钦谕1，徐健2，易正辉1. 精神分裂症患者自杀因素研究进展[J]. 上海交通大学学报（医学版）, 2020, 40(1): 112-.